MedTrace Logo

A Study of the Continuous Glucose Monitoring System for Home Use in Patients With Diabetes

NCT04964752 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2021-07-16

No results posted yet for this study

Summary

Subjects in the upper arm group will have a sensor of the CGM System inserted on each arm (left and right upper arm). Subjects in the abdomen group will have 2 sensors inserted, one on each side of the abdomen (left and right abdomen) The sensors will be placed for 29 days. After sensor insertion, the CGM system should be calibrated with capillary blood glucose readings from a self-monitoring blood glucose meter。

Conditions

Interventions

DEVICE

continuous glucose-monitoring

Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.

Sponsors & Collaborators

  • Powder (Guangzhou) Pharmaceuticals Limited

    collaborator UNKNOWN

  • Powder Pharmaceuticals (HK) Co., Ltd

    collaborator UNKNOWN

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Principal Investigators

  • Elaine Chow, Prof. · Prince of Wales Hospital, the Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-30
Primary Completion
2022-02-28
Completion
2022-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04964752 on ClinicalTrials.gov